In January 2024, the U.S. Food and Drug Administration (FDA) announced that federal regulators instructed drug manufacturers Novo Nordisk and Eli Lilly to eliminate warnings about suicide risks on their weight-loss medications. This decision came after a comprehensive review concluded there was no increased risk of suicidal thoughts or behaviors in users of GLP-1 medications, such as Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. The FDA had previously conducted a preliminary review indicating the likelihood of a small risk, which has now been dismissed. The FDA's revised position aims to harmonize warning labels across GLP-1 receptor agonists, which are also approved for diabetes treatment and do not carry such warnings. The agency stated that today's action would provide consistent messaging across all FDA-approved GLP-1 RA medications. The latest review affirms the safety profile of these drugs, which have gained popularity in recent years for weight management. In a separate but related business context, John Vincent, co-founder of the Leon restaurant chain, expressed optimism about the growing trend of weight-loss injections. He noted that there is a market opportunity for healthier food options tailored to those using weight-loss medications. Recognizing the need for simple and nutritious fare, Vincent plans to revamp the chain’s menu to align with consumer preferences related to low-sugar diets and high protein intake, particularly for customers utilizing such injections. Vincent also highlighted the challenges facing the hospitality industry, such as rising taxes and business rates that have strained profitability. With the end of business rates relief introduced during the COVID-19 pandemic, his chain is undergoing a significant restructuring in response to market pressures. He emphasized the need for Leon to return to its roots in delivering quality food for a broad audience amidst these changing dynamics.